Mounjaro: A Game Changer Beyond Diabetes to Obesity

Mounjaro: A Game Changer Beyond Diabetes to Obesity

Mounjaro (generic name: Tirzepatide) is an innovative chronic disease treatment developed by the global pharmaceutical company Eli Lilly. Although initially approved as a treatment for type 2 diabetes, it has gained immense global attention due to its highly effective weight loss results.

---

1. Mechanism of Action: The World's First 'Dual GIP/GLP-1' Receptor Agonist

While previous treatments like Saxenda or Wegovy mimic only a single hormone called GLP-1, Mounjaro is the first dual combination agent that acts simultaneously on both GIP and GLP-1 incretin hormone receptors.

• GLP-1 Receptor Action: Stimulates insulin secretion, signals the brain that you are full to suppress appetite, and slows down gastric emptying to prolong the feeling of satiety.
• GIP Receptor Action: Improves fat metabolism and alleviates side effects like nausea commonly caused by GLP-1, while drastically enhancing blood sugar control and weight loss through a powerful synergistic effect.

2. Key Benefits and Effects

• Powerful Blood Sugar Control: Shows outstanding efficacy in lowering glycated hemoglobin (HbA1c) levels in type 2 diabetes patients.
• Unprecedented Weight Loss: According to clinical trial (SURMOUNT) results, high-dose administration led to an average weight loss of around 20%, achieving figures comparable to bariatric surgery. (Consequently, the formulation specifically for weight management has been launched in places like the U.S. under the brand name 'Zepbound'.)
• Cardiovascular and Metabolic Improvements: Enhances overall metabolic syndrome indicators by reducing triglycerides, lowering blood pressure, and improving fatty liver conditions.

3. Administration and Dosage

• Dosing Schedule: Administered once a week via subcutaneous injection (abdomen, thigh, or upper arm) on the same day each week.
• Dosage Escalation: Starts at a dose of 2.5mg. Depending on how well the body adapts, the dose is gradually increased at 4-week intervals to 5mg, 7.5mg, 10mg, 12.5mg, up to a maximum of 15mg.

4. Side Effects and Precautions

• Gastrointestinal Side Effects: Nausea, vomiting, diarrhea, constipation, and indigestion can commonly occur during the initial phase of treatment or when increasing the dose. Most symptoms tend to improve over time.
• Risk of Pancreatitis: Although rare, there is a potential risk of acute pancreatitis. If severe, persistent abdominal pain occurs, treatment should be discontinued immediately.
• Contraindications: It should not be used by patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

---

* Mounjaro is a prescription-only medication that requires a proper diagnosis and consultation from a healthcare professional.